The pCloDFl3 encoded bacteriocin release protein (BRP) plays a role in the release of the bacteriocin cloacin DF13. The BRF signal peptide is stable after cleavage, and accumulates in the cytoplasmic membrane. A BRP which is correctly targeted by the unstable murein lipoprotein signal peptide (Lpp-BRP) is not capable of inducing the release of cloacin DF13. To investigate the role of the stable BRP signal peptide in the release of cloacin DF13, the stable BRP signal peptide and the Lpp-BRP were expressed in trans in cells also producing cloacin DF13. Expression and release experiments indicate that the stable signal peptide can complement the Lpp-BRP in the release of cloacin DF13.
Introduction
gent-resistant phospholipase A [2,3,9]. An unusual Bacteriocin release proteins (BRPs), also known as 'lysis proteins' or ' kil proteins', are involved in the transfer of colicins and cloacin DF13 from the Escherichia coli cytoplasm to the culture medium [1, 2] . BRPs are synthesized as small prolipoproteins which are slowly processed by the lipoprotein specific signal peptidase SPaseII [3, 4] . As a result of this processing, a mature fatty-acylated BRP and a stable signal peptide accumulate in the cell envelope [5, 6] . The mature BRPs are predominantly located in the outer membrane [1, 7, 8] and activate the deterfeature of the BRP signal peptides is that they are resistant to proteolytic degradation [3, 10] . The stable signal peptides accumulate in the cytoplasmic membrane i&7,11], in which they cause physical changes Nl.
Gene replacement experiments showed that the stable signal peptide of the pCloDF13 encoded BRP plays a role in bacteriocin release. A BRP construct, in which the stable signal peptide was replaced by the unstable murein lipoprotein (Lpp) signal peptide, is correctly processed, fatty-acylated, and targeted to the outer membrane [8, 11] . However, this hybrid Lpp-BRP construct is not active in the release of cloacin DF13 [6] . Hybrid Lpp/BRP signal peptides of intermediary stability were found to be active in l the release of cloacin DF13, but to a lesser extent than the original stable signal peptide [13] .
Plasmids
In a previous study [ll] , the stable pCloDF13-enPlasmid pJL38 encodes the pCloDF13-derived coded signal peptide was expressed as a separate stable BRP signal peptide under the control of the entity. This signal peptide is localized in the cyto-IPTG-inducible lpp / lac tandem promoter/operator plasmic membrane, as the stable signal peptide after (P lyp,loc) [11, 13] . This plasmid contains a unique processing of the BRP precursor. High level expresXbaI restriction site in the region between the prosion of the stable signal peptide as a separate entity moter and the signal peptide coding sequence, and a is deleterious to the cells [12] . However, cloacin unique Hind111 restriction site in the 3' non-trans-DF13 is not found in the periplasm or in the extracellated region. Plasmid pJL38 was used to isolate the lular medium, when the stable signal peptide is small XbaI-Hind111 fragment encoding the stable expressed without the mature BRP [ll] .
signal peptide. In this study, the role of the stable pCloDF13-BRP signal peptide in bacteriocin release is investigated by expressing the stable signal peptide and Lpp-BRP in trans, in cloacin DF13-producing cells.
Materials and methods

Bacterial strains and media
Escherichia coli C600 F-thr-1 leuB6 thi-1 lacy1 supE44 rfbD1 JhuA21 mcrA1 was used for initial cloning. The sup-E. coli strain FIT'4170 A(tonB trpAE) argE(Am) glyV5.5 [14] was used in cloacin DF13 release experiments to ensure termination of protein synthesis at the TAG stop codon of the stable signal peptide.
Plasmid pOM88ElppssBRP
was used to construct a plasmid encoding the genes for Lpp-BRP and the stable signal peptide, each under the control of separately inducible promoters. This plasmid is a pBR322-derivative which contains the Lpp-BRP gene under the control of the mytomicin C inducible SOS promoter (P,,,) , and the K88 gene encoding the periplasmic chaperone FaeE under the control of P ,pp,lur. The faeE gene was replaced by the gene encoding the stable signal peptide. This was carried out by exchanging the XbaI-Hind111 fragment of pOM88ElppssBRP for the small XbaI-Hind111 fragment of pJL38. The resulting plasmid encodes the P,,,-controlled Lpp-BRP and the PIP,,, ,,,-controlled stable signal peptide, and was designated pFJ38lpps-sBRP ( Fig. 1) . pFJ38lppssBRP was used to simulta-YT medium [15] was used as the culture medium. MgCl, (20 mM) was added to reduce BRP-induced quasi-lysis [2] . Glucose (2%) was added to repress the isopropyl-P-D-thiogalactopyranoside (IPTG) inducible promoter in the absence of IPTG. The antibiotics ampicillin (100 pg/ml) and tetracycline (12.5 pg/ml) were added when required. The pACYC18Cderivative pJL25 encodes cloacin DF13 and its immunity protein under the control of the Psos 141. This plasmid was used to express cloacin DF13 in E. cofi cells which also harbored pFJ38lppssBRP.
Cloacin DF13 release experiments and protein analysis
Cells of E. coli FTP4170, harboring pJL25 and pFJ38lppssBRP, were cultured in 80 ml of medium in 250 ml bottles to a culture turbidity at 660 nm of 0.2 (OD,, -0.2). Subsequently, the cultures were divided into 20-ml portions, which were further incubated in lOO-ml bottles. IPTG (0.1 or 1.0 mM) was added to induce the stable signal peptide encoded by pFJ38lppssBRP. Mitomycin C (1.0 pg/ml) was added to induce both cloacin DF13 and Lpp-BRP, encoded by pJL25 and pFJ38lppssBRP, respectively. Growth was monitored by measuring the OD,, at regular intervals, and samples were taken at various time points. The cells were separated from the culture medium by centrifugation and solubilized in solubilization mix [20] . Cloacin DF13 in the culture supematant fraction was precipitated by adding trichloro acetic acid to a final concentration of lo%, using tRNA as a carrier. The precipitate was collected and solubilized in the same volume of solubilization mix as was used for cells. The solubilized cells and the precipitate were analyzed by SDS-PAGE using 11% polyacrylamide gels. Immunoblotting was carried out to detect either cloacin DF13 or the cytoplasmic marker protein DnaK. The proteins were visualized by chemiluminescence using the ECL Kit from Amersham. Digitized images (The Imager, Appligene) were used to quantify chemiluminescent proteins with ImageQuaNT software (Molecular Dynamics, Inc.). Reprobing of blotted proteins was enabled by stripping the blots [21] . Cloacin DF13 antiserum has been described previously [22] . DnaK antiserum was a generous gift from B. Bukau.
Results and discussion
The stable pCloDF13-BRP signal peptide accumulates in the cytoplasmic membrane [ll] , and plays Lpp-BRP and the pJL25-encoded cloacin DF13 were induced with 1.0 pg/ml of mytomycin C. Expression of the pFJ38lppssBRP-encoded stable signal peptide was not induced (lanes l-4), induced at a moderate level or at a high level (0.1 mM IPTG, lanes S-8; 1.0 mM IPTG, lanes 9-12). Samples were taken 3 and 5 h after induction, and the cellular fractions (C) and spent medium (E) were analyzed. a role in bacteriocin release [6, 13] . In the wild-type situation, the signal peptide is cleaved-off from the BRP precursor [14] . We investigated whether the separately expressed stable pCloDF13-BRP signal peptide plays a role in bacteriocin release. This study was carried out in cells which simultaneously produce cloacin DF13, the Lpp-BRP precursor, and the stable BRP signal peptide (Fig. 2) . In these complementation experiments, expression of cloacin DF13 and Lpp-BRP was induced with 1.0 pg/ml of mytomicin C. Expression of the stable signal peptide was induced with various concentrations of IPTG (0.0, 0.1, or 1.0 mM IPTG, respectively). Cloacin DF13 remained in the cells, when the stable signal peptide was not induced (Fig. 2, lanes 1 and 3) . Significant amounts of the bacteriocin were found in the extracellular medium upon moderate and high level induction of the stable signal peptide (Fig. 2,  lanes 6, 8, 10 and 12 ). The amount of extracellular cloacin DF13 increased with time ( Fig. 2; 3 h: lanes 6 and 10; 5 h: lanes 8 and 12). These observations show that the stable signal peptide, when expressed as a separate entity, supports the BRP-mediated release of cloacin DF13.
Cell growth was slightly affected when expression of the stable signal peptide was induced (Fig. 3) . As revealed by quantification of chemiluminescent proteins, leakage of the cytoplasmic marker protein DnaK remained below 10% under all conditions (not shown). These observations indicate that no signifi- cant cell lysis had occurred during these release experiments.
As mentioned above, cells which were highly induced for Lpp-BRP, released cloacin DF13 both upon moderate and high level induction of the stable signal peptide (Fig. 2, lanes 6, 8, 10 and 12 ). This indicates that under each condition a sufficient amount of the stable signal peptide was produced to allow cloacin DFlS-release.
Cells which were moderately induced for Lpp-BRP released cloacin DF13 upon high level induction of the stable signal peptide (not shown). This suggests that increased amounts of the stable signal peptide are needed to support cloacin DF13-release, when the amounts of mature BRP are limited. Apparently, when the concentration of one of the peptides is too low for bacteriocin release, an increase in the concentration of the other peptide can complement this defect. This implies that mature BRP and the stable signal peptide co-operate in bacteriocin release.
The observations described above show that the stable signal peptide plays a role in bacteriocin release, when it is expressed in trans with Lpp-BRP. Apparently, how the stable signal peptide reaches the cytoplasmic membrane is not important for the release of cloacin DF13. Insertion of signal peptides has been shown to result in a loss of bilayer structure [23, 24] . Possibly, accumulation of stable signal peptides causes alterations in the structure of the cell envelope 17,251. Signal peptides of intermediate stability also support bacteriocin release [13] . Furthermore, preliminary results hint at the possibility that a heavily over-expressed unstable signal peptide can also complement Lpp-BRP. This may imply that the accumulation of a signal peptide, rather than a specific (stable) BRP signal peptide is important for bacteriocin release.
